184 related articles for article (PubMed ID: 16137213)
41. The impact of diabetes counseling and education: clinical and cost outcomes from a large population of US managed care patients with type 2 diabetes.
Sullivan SD; Dalal MR; Burke JP
Diabetes Educ; 2013; 39(4):523-31. PubMed ID: 23640302
[TBL] [Abstract][Full Text] [Related]
42. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.
McAdam-Marx C; McGarry LJ; Hane CA; Biskupiak J; Deniz B; Brixner DI
J Manag Care Pharm; 2011 Sep; 17(7):531-46. PubMed ID: 21870894
[TBL] [Abstract][Full Text] [Related]
43. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
[TBL] [Abstract][Full Text] [Related]
44. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes.
Bibeau WS; Fu H; Taylor AD; Kwan AY
J Manag Care Spec Pharm; 2016 Nov; 22(11):1338-1347. PubMed ID: 27783549
[TBL] [Abstract][Full Text] [Related]
45. COMPARING CLINICAL OUTCOMES AND COSTS FOR DIFFERENT TREATMENT INTENSIFICATION APPROACHES IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN: ADDING GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS VERSUS ADDING RAPID-ACTING INSULIN OR INCREASING BASAL INSULIN DOSE.
Levin P; Fan T; Song X; Nero D; Davis B; Chu BC
Endocr Pract; 2017 Nov; 23(11):1316-1324. PubMed ID: 28816532
[TBL] [Abstract][Full Text] [Related]
46. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.
Grima DT; Thompson MF; Sauriol L
Pharmacoeconomics; 2007; 25(3):253-66. PubMed ID: 17335310
[TBL] [Abstract][Full Text] [Related]
47. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
[TBL] [Abstract][Full Text] [Related]
48. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
[TBL] [Abstract][Full Text] [Related]
49. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
Bergeson JG; Worley K; Louder A; Ward M; Graham J
J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
[TBL] [Abstract][Full Text] [Related]
50. Descriptive Analysis of Long- and Intermediate-Acting Insulin and Key Safety Outcomes in Adults with Type 2 Diabetes Mellitus.
Kent DJ; McMahill-Walraven CN; Panozzo CA; Pawloski PA; Haynes K; Marshall J; Brown J; Eichelberger B; Lockhart CM
J Manag Care Spec Pharm; 2019 Nov; 25(11):1162-1171. PubMed ID: 31405345
[TBL] [Abstract][Full Text] [Related]
51. Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study.
Mody R; Huang Q; Yu M; Patel H; Zhang X; Wang L; Grabner M
BMJ Open Diabetes Res Care; 2019; 7(1):e000884. PubMed ID: 31875137
[TBL] [Abstract][Full Text] [Related]
52. Maintenance of Clinical Endpoints After Discharge from a Pharmacist-Managed Risk Reduction Clinic at a Veterans Affairs Medical Center.
Sherrill CH; Pentecost A; Wood EE
J Manag Care Spec Pharm; 2016 Jan; 22(1):14-20. PubMed ID: 27015047
[TBL] [Abstract][Full Text] [Related]
53. Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes.
Luo J; Khan NF; Manetti T; Rose J; Kaloghlian A; Gadhe B; Jain SH; Gagne JJ; Kesselheim AS
JAMA; 2019 Jan; 321(4):374-384. PubMed ID: 30694321
[TBL] [Abstract][Full Text] [Related]
54. Information technology for the treatment of diabetes: improving outcomes and controlling costs.
Wyne K
J Manag Care Pharm; 2008 Mar; 14(2 Suppl):S12-7. PubMed ID: 18331115
[TBL] [Abstract][Full Text] [Related]
55. Perioperative hemoglobin A1c as a predictor of deep infection following single-level lumbar decompression in patients with diabetes.
Cancienne JM; Werner BC; Chen DQ; Hassanzadeh H; Shimer AL
Spine J; 2017 Aug; 17(8):1100-1105. PubMed ID: 28343046
[TBL] [Abstract][Full Text] [Related]
56. The relationship between HbA1c reduction and healthcare costs among patients with type 2 diabetes: evidence from a U.S. claims database.
Lage MJ; Boye KS
Curr Med Res Opin; 2020 Sep; 36(9):1441-1447. PubMed ID: 32643451
[TBL] [Abstract][Full Text] [Related]
57. Improved Glycemic Control Outcomes Regardless of Mental Health Disorders in a Pharmacist-Endocrinologist Diabetes Intense Medical Management (DIMM) "Tune Up" Clinic.
Morello CM; Nguyen T; Tao L; Hirsch JD
Ann Pharmacother; 2020 Sep; 54(9):858-865. PubMed ID: 32100551
[No Abstract] [Full Text] [Related]
58. Health Care Costs, Hospital Admissions, and Glycemic Control Using a Standalone, Real-Time, Continuous Glucose Monitoring System in Commercially Insured Patients With Type 1 Diabetes.
Gill M; Zhu C; Shah M; Chhabra H
J Diabetes Sci Technol; 2018 Jul; 12(4):800-807. PubMed ID: 29737202
[TBL] [Abstract][Full Text] [Related]
59. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program.
Lawrence DB; Ragucci KR; Long LB; Parris BS; Helfer LA
J Manag Care Pharm; 2006; 12(6):466-71. PubMed ID: 16925454
[TBL] [Abstract][Full Text] [Related]
60. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
Robinson RL; Long SR; Chang S; Able S; Baser O; Obenchain RL; Swindle RW
J Manag Care Pharm; 2006; 12(1):43-54. PubMed ID: 16420107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
